当前位置: 首页 >> 检索结果
101. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
作者: Jan A Burger.;Alessandra Tedeschi.;Paul M Barr.;Tadeusz Robak.;Carolyn Owen.;Paolo Ghia.;Osnat Bairey.;Peter Hillmen.;Nancy L Bartlett.;Jianyong Li.;David Simpson.;Sebastian Grosicki.;Stephen Devereux.;Helen McCarthy.;Steven Coutre.;Hang Quach.;Gianluca Gaidano.;Zvenyslava Maslyak.;Don A Stevens.;Ann Janssens.;Fritz Offner.;Jiří Mayer.;Michael O'Dwyer.;Andrzej Hellmann.;Anna Schuh.;Tanya Siddiqi.;Aaron Polliack.;Constantine S Tam.;Deepali Suri.;Mei Cheng.;Fong Clow.;Lori Styles.;Danelle F James.;Thomas J Kipps.; .
来源: N Engl J Med. 2015年373卷25期2425-37页
Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma.
103. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.
作者: Brian Claggett.;Milton Packer.;John J V McMurray.;Karl Swedberg.;Jean Rouleau.;Michael R Zile.;Pardeep Jhund.;Martin Lefkowitz.;Victor Shi.;Scott D Solomon.; .
来源: N Engl J Med. 2015年373卷23期2289-90页 110. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
作者: Marc A Pfeffer.;Brian Claggett.;Rafael Diaz.;Kenneth Dickstein.;Hertzel C Gerstein.;Lars V Køber.;Francesca C Lawson.;Lin Ping.;Xiaodan Wei.;Eldrin F Lewis.;Aldo P Maggioni.;John J V McMurray.;Jeffrey L Probstfield.;Matthew C Riddle.;Scott D Solomon.;Jean-Claude Tardif.; .
来源: N Engl J Med. 2015年373卷23期2247-57页
Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.
111. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.
作者: Thomas Rauen.;Frank Eitner.;Christina Fitzner.;Claudia Sommerer.;Martin Zeier.;Britta Otte.;Ulf Panzer.;Harm Peters.;Urs Benck.;Peter R Mertens.;Uwe Kuhlmann.;Oliver Witzke.;Oliver Gross.;Volker Vielhauer.;Johannes F E Mann.;Ralf-Dieter Hilgers.;Jürgen Floege.; .
来源: N Engl J Med. 2015年373卷23期2225-36页
The outcomes of immunosuppressive therapy, when added to supportive care, in patients with IgA nephropathy are uncertain.
115. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.
作者: Jean-Michel Molina.;Catherine Capitant.;Bruno Spire.;Gilles Pialoux.;Laurent Cotte.;Isabelle Charreau.;Cecile Tremblay.;Jean-Marie Le Gall.;Eric Cua.;Armelle Pasquet.;François Raffi.;Claire Pintado.;Christian Chidiac.;Julie Chas.;Pierre Charbonneau.;Constance Delaugerre.;Marie Suzan-Monti.;Benedicte Loze.;Julien Fonsart.;Gilles Peytavin.;Antoine Cheret.;Julie Timsit.;Gabriel Girard.;Nicolas Lorente.;Marie Préau.;James F Rooney.;Mark A Wainberg.;David Thompson.;Willy Rozenbaum.;Veronique Doré.;Lucie Marchand.;Marie-Christine Simon.;Nicolas Etien.;Jean-Pierre Aboulker.;Laurence Meyer.;Jean-François Delfraissy.; .
来源: N Engl J Med. 2015年373卷23期2237-46页
Antiretroviral preexposure prophylaxis has been shown to reduce the risk of human immunodeficiency virus type 1 (HIV-1) infection in some studies, but conflicting results have been reported among studies, probably due to challenges of adherence to a daily regimen.
|